trending Market Intelligence /marketintelligence/en/news-insights/trending/TB8xM04t1uja8kEzh68bRg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Mylan to recall ulcer drug from US market over cancer-causing impurity

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Mylan to recall ulcer drug from US market over cancer-causing impurity

Mylan NV initiated a voluntary recall of three lots of its Nizatidine capsules in the U.S. market after detecting traces of a potentially cancer-causing substance called N-Nitrosodimethylamine, commonly known as NDMA.

The U.K.-based pharmaceutical company did not receive any reports of adverse events directly related to the recalled batches.

Nizatidine is used to treat ulcers of the stomach and intestines and prevent them from coming back after they have healed. It is also used to treat certain other stomach and throat problems including gastroesophageal reflux disease. The medication works by decreasing the amount of acid the stomach makes.

Previously, Mylan was among the companies that recalled several lots of their generic ranitidine drugs from the U.S. market after finding elevated levels of NDMA in the products.